When looking at adverse side effects, it should also be remembered that in the historical trials the bisantrene dose was much higher than will be used in the upcoming breast cancer cardioprotection trial.
Ann: Ethics submission to commence cardioprotection trial, page-42
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.020(1.19%) |
Mkt cap ! $282.8M | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.67 | $1.61 | $153.5K | 94.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 4080 | 1 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |